The Barre-Montpelier Times Argus

Asahi Kasei Announces Initiation of Phase I Clinical Trial for Novel Peptide Candidate Targeting Autoimmune Diseases

Asahi Kasei, a diversified global company, today announced the initiation of a Phase I clinical trial for AK1940, a novel peptide-based investigational compound developed to address significant unmet ...
The Barre-Montpelier Times Argus

PeptiDream Announces the Initiation of Phase 1 Clinical Trial by Its Collaboration Partner

PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter “PeptiDream”) today announced that Asahi Kasei Therapeutics (Headquarters: Chiyoda-ku ...

Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism

Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-479 in Healthy Volunteers Data Anticipated in ...

Orvida Pharma (formerly Kamari Pharma) Announces Favorable Phase 1a Safety Data for KM-023, a Potential First-in-Disease Oral TRPV3 Inhibitor, and Initiation of Phase 1b Study ...

First Olmsted syndrome patient dosed in global Phase 1b studyCompany now operating under its new name, Orvida PharmaNESS ZIONA, Israel, April ...

Sparian Biosciences Announces Initiation of Phase 1 Clinical Trial of SBS-147 Next Generation Arylepoxamide Agonist for the Treatment of Pain Funded by a $15M NI…

Phase 1 clinical trial will evaluate the safety, tolerability, and pharmacokineticsSBS-147 is a novel and potent oral ...
Seeking Alpha

Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata

SAN FRANCISCO, March 5, 2024 /PRNewswire/ -- Nektar Therapeutics (NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced the initiation of its ...
Business Wire

Khondrion Announces First Patient Dosed in Pivotal Phase 3 KHENERFIN Study of Sonlicromanol in Mitochondrial DNA 3243A>G Primary Mitochondrial Disease

Khondrion announced that the first patient has been dosed in the Phase 3 study evaluating sonlicromanol in m.3243A>G Primary ...
Business Wire

Genethon and Hansa Biopharma Announce Initiation of a Phase 2 Trial of imlifidase as a Pre-Treatment to GNT-0003 in Severe Crigler-Najjar Syndrome

LUND, Sweden & EVRY, France--(BUSINESS WIRE)--Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA) and Genethon, a pioneer and a leader in gene therapy research and development for rare genetic diseases, ...
Seeking Alpha

Viking Therapeutics Announces Initiation of Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

SAN DIEGO, Sept. 6, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...
Nasdaq

Enlivex receives authorization for initiation of Phase I trial of Allocetra

Enlivex Therapeutics (ENLV) announced that the Israeli Ministry of Health authorized the initiation of an investigator-initiated Phase I trial to evaluate the safety, tolerability and initial efficacy ...
Nasdaq

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults

SAN DIEGO, Sept. 11, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, ...